Our top pick for
Building a portfolio
Soleno Therapeutics, Inc is a diagnostics & research business based in the US. Soleno Therapeutics shares (SLNO) are listed on the NASDAQ and all prices are listed in US Dollars. Soleno Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of USD$98.9 million.
|52-week range||USD$1.15 - USD$4.39|
|50-day moving average||USD$1.86|
|200-day moving average||USD$2.0068|
|Wall St. target price||USD$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.726|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-38.72%|
|Return on equity TTM||-81.46%|
|Market capitalisation||USD$98.9 million|
TTM: trailing 12 months
There are currently 1.7 million Soleno Therapeutics shares held short by investors – that's known as Soleno Therapeutics's "short interest". This figure is 125.4% up from 767,270 last month.
There are a few different ways that this level of interest in shorting Soleno Therapeutics shares can be evaluated.
Soleno Therapeutics's "short interest ratio" (SIR) is the quantity of Soleno Therapeutics shares currently shorted divided by the average quantity of Soleno Therapeutics shares traded daily (recently around 2.7 million). Soleno Therapeutics's SIR currently stands at 0.65. In other words for every 100,000 Soleno Therapeutics shares traded daily on the market, roughly 650 shares are currently held short.
However Soleno Therapeutics's short interest can also be evaluated against the total number of Soleno Therapeutics shares, or, against the total number of tradable Soleno Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Soleno Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Soleno Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0277% of the tradable shares (for every 100,000 tradable Soleno Therapeutics shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Soleno Therapeutics.
Find out more about how you can short Soleno Therapeutics stock.
We're not expecting Soleno Therapeutics to pay a dividend over the next 12 months.
Soleno Therapeutics's shares were split on a 1:5 basis on 5 October 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Soleno Therapeutics shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Soleno Therapeutics shares which in turn could have impacted Soleno Therapeutics's share price.
Over the last 12 months, Soleno Therapeutics's shares have ranged in value from as little as $1.15 up to $4.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Soleno Therapeutics's is 0.4368. This would suggest that Soleno Therapeutics's shares are less volatile than average (for this exchange).
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.